Products Categories
CAS No.: | 9001-01-8 |
---|---|
Name: | Kallikrein |
Molecular Structure: | |
Formula: | N/A |
Molecular Weight: | 0 |
Synonyms: | Arginineesteropeptidase;Bradykininogenase;Callicrein;Circuletin;Depot-Glumorin;Depot-Padutin;Dilminal D;E.C. 3.4.21.8;E.C. 3.4.4.21;Follipsin;Glumorin;Kalirechin;Kallidinogenase;Kallikrein esterase;Kininogenase;Kininogenin;Onokrein P;Padreatin;Padukrein;Padutin;Pancreatic kallikrein;Prokrein;Promotin;Urinary kallikrein;Urokallikrein;Yikai;SK 827;Substance R (enzyme); |
EINECS: | 232-574-5 |
Solubility: | Soluble in water (10%), diluted alcohol, insoluble in concentrated ethanol and general organic solvents |
Appearance: | White or off-white powder |
Hazard Symbols: | B |
PSA: | 0.00000 |
LogP: | 0.00000 |
The Kallikrein, with the CAS registry number 9001-01-8, is also known as Kallidinogenase. Its EINECS number is 232-572-4. Its classification codes are: (1)Coagulants; (2)Drug / Therapeutic Agent; (3)Fertility Agents; (4)Fertility Agents, Male; (5)Hematologic Agents; (6)Mutation data; (7)Reproductive Control Agents; (8)Reproductive Effect. Its storage temperature is 2-8°C. Moreover, it should be protected from light. It is mainly used as vasodilator. What's more, it can be used to cure cerebral arteriosclerosis, endarteritisobliterans, essential hypertension, angina, thromboangiitisobliterans. It is synthesised as an inactive precursor, prekallikrein, which must undergo proteolytic processing to become activated.
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intravenous | > 40mL/kg (40mL/kg) | Kiso to Rinsho. Clinical Report. Vol. 27, Pg. 2589, 1993. | |
mouse | LD50 | oral | > 40mL/kg (40mL/kg) | Kiso to Rinsho. Clinical Report. Vol. 27, Pg. 2589, 1993. | |
mouse | LD50 | subcutaneous | > 40mL/kg (40mL/kg) | Kiso to Rinsho. Clinical Report. Vol. 27, Pg. 2589, 1993. | |
rat | LD50 | intravenous | > 40mL/kg (40mL/kg) | KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED | Kiso to Rinsho. Clinical Report. Vol. 27, Pg. 2589, 1993. |
rat | LD50 | oral | > 40mL/kg (40mL/kg) | Kiso to Rinsho. Clinical Report. Vol. 27, Pg. 2589, 1993. | |
rat | LD50 | subcutaneous | > 40mL/kg (40mL/kg) | Kiso to Rinsho. Clinical Report. Vol. 27, Pg. 2589, 1993. |